Simplex Trading’s Cullinan Oncology CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$67.4K Sell
3,700
-6,400
-63% -$95K ﹤0.01% 5990
2026
Q1
$144K Buy
10,100
+4,500
+80% +$57.8K ﹤0.01% 4677
2025
Q4
$58K Sell
5,600
-26,600
-83% -$240K ﹤0.01% 5528
2025
Q3
$190K Sell
32,200
-28,700
-47% -$210K ﹤0.01% 4992
2025
Q2
$458K Buy
60,900
+57,000
+1,462% +$458K ﹤0.01% 3590
2025
Q1
$29K Buy
3,900
+100
+3% +$960 ﹤0.01% 6264
2024
Q4
$46K Buy
3,800
+400
+12% +$5.75K ﹤0.01% 5955
2024
Q3
$56K Buy
+3,400
New +$60.3K ﹤0.01% 5785
2024
Q2
Sell
-2,400
Closed -$40K 8873
2024
Q1
$40K Buy
2,400
+1,100
+85% +$17K ﹤0.01% 6455
2023
Q4
$13K Buy
1,300
+100
+8% +$886 ﹤0.01% 7229
2023
Q3
$10K Buy
1,200
+200
+20% +$2.08K ﹤0.01% 7161
2023
Q2
$10K Buy
+1,000
New +$10.6K ﹤0.01% 7376
2022
Q4
Sell
-200
Closed -$2K 9296
2022
Q3
$2K Sell
200
-200
-50% -$2.69K ﹤0.01% 9242
2022
Q2
$5K Sell
400
-300
-43% -$3.4K ﹤0.01% 8801
2022
Q1
$7K Buy
700
+600
+600% +$8.11K ﹤0.01% 9149
2021
Q4
$1K Buy
+100
New +$2K ﹤0.01% 10156

Other funds holding CGEM

Simplex Trading's CGEM Position: Q2 2026 in Review

Simplex Trading reduced its Cullinan Oncology (CGEM) stake by 1.1% in Q2 2026, selling an estimated $2.78K and leaving 17,444 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.

Simplex Trading first reported a position in CGEM in Q2 2022 and has held it in 13 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Simplex Trading held 17,444 shares of Cullinan Oncology worth $318K as of Q2 2026.
  • Simplex Trading sold 187 Cullinan Oncology shares in Q2 2026, an estimated $2.78K.
  • Cullinan Oncology made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4159 holding.
  • Simplex Trading first reported a position in Cullinan Oncology in Q2 2022 and has held it in 13 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.